{"id":35712,"date":"2025-12-06T15:06:43","date_gmt":"2025-12-06T15:06:43","guid":{"rendered":"https:\/\/metaverseplanet.net\/blog\/?p=35712"},"modified":"2026-01-05T12:44:09","modified_gmt":"2026-01-05T12:44:09","slug":"first-drug-of-its-kind-developed-to-repair-dna-damage","status":"publish","type":"post","link":"https:\/\/metaverseplanet.net\/blog\/first-drug-of-its-kind-developed-to-repair-dna-damage\/","title":{"rendered":"First Drug of Its Kind Developed to Repair DNA Damage"},"content":{"rendered":"\n

Scientists have developed an experimental drug<\/strong> capable of repairing DNA<\/strong> and healing tissue damage<\/strong>. Named TY1<\/strong>, this drug stands out as the first prototype of a new class of drugs aimed at correcting tissues damaged in heart attacks<\/strong>, inflammatory diseases<\/strong>, and other conditions.<\/p>\n\n\n\n

First Example of a New Class of Drugs<\/strong> TY1<\/strong> is a laboratory-produced version of an RNA molecule<\/strong> naturally found in the body. The research team demonstrated that TY1 increases the activity of the TREX1 gene<\/strong>, allowing immune cells<\/strong> to clear damaged DNA<\/strong> and contribute to tissue repair<\/strong>.<\/p>\n\n\n\n

The development process of TY1 spans over twenty years<\/strong>. The starting point of the invention dates back to the isolation of progenitor cells<\/strong> from human heart tissue in a laboratory at Johns Hopkins University<\/strong>. Progenitor cells, which share properties similar to stem cells<\/strong>, can create new healthy tissue in a more focused manner and contribute to heart regeneration<\/strong>.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

In studies conducted at Cedars-Sinai<\/strong>, Ahmed Ibrahim<\/strong> discovered that heart progenitor cells release small vesicles filled with RNA molecules, known as exosomes<\/strong>. The RNAs in these vesicles guide the repair and regeneration of injured tissues. Eduardo Marban<\/strong>, Director of the Cedars-Sinai Smidt Heart Institute<\/strong>, emphasizes that TY1 offers the ability to repair the body without using stem cells and represents the first example of a new class of drugs called “exomers<\/strong>.”<\/p>\n\n\n\n

TY1 possesses the structure of existing RNA drugs<\/strong> and functions like its natural counterpart. The drug’s primary function is to activate the TREX1 gene<\/strong> to boost the effectiveness of immune cells<\/strong> around damaged DNA, thereby ensuring the clearance of DNA damage and the repair of tissues. This process accelerates recovery by minimizing the damage that occurs especially after a heart attack<\/strong>.<\/p>\n\n\n\n

Interestingly, TY1’s effect is not limited to heart tissue<\/strong>. Ibrahim states that by enhancing DNA repair<\/strong>, TY1 could potentially provide benefits in conditions where the body attacks its own healthy tissues, such as autoimmune diseases<\/strong>. This mechanism offers a completely new approach to tissue healing<\/strong>, paving the way for new treatment options for various diseases.<\/p>\n\n\n\n

Following successful results in animal models<\/strong>, TY1 will undergo clinical trials<\/strong> in humans. If it performs as expected, this drug will open the doors to a new era in treating cellular damage<\/strong> caused by sudden events and chronic inflammation<\/strong>.<\/p>\n\n\n\n

You Might Also Like;<\/h3>\n\n\n